<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00080977</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000357581</org_study_id>
    <secondary_id>CMC-10-01-01AH</secondary_id>
    <nct_id>NCT00080977</nct_id>
  </id_info>
  <brief_title>High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2</brief_title>
  <official_title>Treatment of Patients With Metastatic Renal Cell Carcinoma Who Have Failed Low Dose Intensity Interleukin-2 With High-Dose Intravenous Recombinant Interleukin-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blumenthal Cancer Center at Carolinas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill renal cell&#xD;
      carcinoma (kidney cancer) cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well high-dose intravenous interleukin-2 works&#xD;
      in treating patients with metastatic renal cell carcinoma that has not responded to previous&#xD;
      low-dose intravenous or subcutaneous interleukin-2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate (complete, partial, and minor) in patients with metastatic&#xD;
           renal cell carcinoma who failed prior low-dose intravenous or subcutaneous interleukin-2&#xD;
           (IL-2) when treated with high-dose intravenous IL-2.&#xD;
&#xD;
        -  Determine the overall survival, disease-free survival, and time to progression in&#xD;
           patients treated with this drug.&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      Patients receive high-dose interleukin-2 IV every 8 hours for 15 doses followed 7-10 days&#xD;
      later by another 15 doses (course 1).&#xD;
&#xD;
      Patients are assesed for response 2 months after initiation of treatment. Patients with&#xD;
      responding or stable disease receive a second course of therapy. Patients with an ongoing&#xD;
      response receive subsequent courses of treatment in the absence of unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 6 months for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 1998</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed renal cell carcinoma&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
               -  No pure papillary or sarcomatoid variants&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Failed prior subcutaneous OR intravenous (dose ≤ 50,000 IU/kg/day) interleukin-2&#xD;
&#xD;
               -  Documented disease progression&#xD;
&#xD;
          -  No estimated hepatic replacement by tumor &gt; 25% by CT scan or MRI&#xD;
&#xD;
          -  No tumor involving the CNS or a major nerve&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count ≥ 80,000/mm^3&#xD;
&#xD;
          -  No sites of ongoing bleeding&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Bilirubin ≤ 1.4 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 3 times normal&#xD;
&#xD;
          -  PT or PTT INR ≤ 1.2&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C virus negative&#xD;
&#xD;
          -  No coagulation disorders&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.6 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No ongoing ischemia*&#xD;
&#xD;
          -  No cardiac dysfunction*&#xD;
&#xD;
          -  No abnormal ejection fraction* NOTE: *A cardiac stress test is indicated for all&#xD;
             patients ≥ 50 years of age and for any patient with possible cardiac disease as&#xD;
             suggested by history, physical exam, or electrocardiogram&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  FEV_1 ≤ 65% of predicted*&#xD;
&#xD;
          -  Vital capacity ≤ 65% of predicted* NOTE: *Pulmonary function tests are to be performed&#xD;
             on any patient with a significant smoking history or suspected pulmonary disease&#xD;
             either by history, physical exam, or radiograph&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No AIDS&#xD;
&#xD;
          -  No systemic infections&#xD;
&#xD;
          -  No other malignancy except carcinoma in situ&#xD;
&#xD;
          -  No psychiatric illness that would preclude study participation or compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 28 days since other prior treatment for renal cell cancer&#xD;
&#xD;
          -  No concurrent immunosuppressive agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard L. White, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Blumenthal Cancer Center at Carolinas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Blumenthal Cancer Center at Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232-2861</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2005</verification_date>
  <study_first_submitted>April 7, 2004</study_first_submitted>
  <study_first_submitted_qc>April 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2004</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

